Blood test score helps predict COVID-19 severity

By staff writers

October 15, 2020 -- A team of researchers from the Royal College of Surgeons in Ireland (RCSI) University of Medicine and Health Sciences has developed a blood test score that can help predict COVID-19 disease severity, according to a study published on October 14 in EBioMedicine.

The Dublin-Boston score is intended to help physicians identify COVID-19 patients who may benefit from therapies such as steroids and admission to intensive care. It predicts the severity of the illness on day seven of infection, after measuring the patient's blood for four days, by tracking levels of interleukin-6 (IL-6) and IL-10, molecules that control the body's immune system and inflammation. Levels of both these molecules are altered in patients with severe COVID-19.

The score is based on one-point increases, each of which are associated with 5.6 times higher odds for severe illness.

"More informed prognosis could help determine when to escalate or de-escalate care, a key component of the efficient allocation of resources during the current pandemic" said study senior author Dr. Gerry McElvaney of RCSI. "The score may also have a role in evaluating whether new therapies designed to decrease inflammation in COVID-19 actually provide benefit."

Detecting SARS-CoV-2 in blood may be early indicator of severe disease
A blood test that measures SARS-CoV-2 RNA when patients are admitted to the hospital with COVID-19 symptoms can be a powerful diagnostic tool to predict...
Biomarkers to determine COVID-19 odds: GW researchers
George Washington (GW) University researchers have found five biomarkers associated with higher odds of clinical deterioration and death in COVID-19 patients.
San Diego research institutes study spread of COVID-19
San Diego medical and scientific research institutes launched a large-scale COVID-19 screening research study with an initial focus on evaluating healthcare...
LabCorp gives employers a hand with screening staff for coronavirus
LabCorp is launching return-to-work services to help employers screen their staff for COVID-19, including antibody blood tests.
Abbott secures EUA for SARS-CoV-2 antibody blood test
Abbott has received an emergency use authorization (EUA) from the U.S. Food and Drug Administration for a SARS-CoV-2 immunoglobulin G lab-based serology...

Copyright © 2020

Last Updated ls 10/15/2020 12:53:51 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current